Eps Corp operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Eps Corp with three other
companies in this sector in Japan:
Shin Nippon Biomedical Laboratories Ltd
sales of 17.24 billion Japanese Yen [US$161.06 million]
of which 75%
was Pre-Clinical Business),
Sosei Group Corporation
(18.90 billion Japanese Yen [US$176.54 million]
of which 99%
was Overseas Pharmaceutical Business), and
Takara Bio Inc
(29.38 billion Japanese Yen [US$274.36 million]
of which 90%
was Bio support).
Eps Corp reported sales of ¥60.48 billion (US$564.90 million)
September of 2017.
increase of 14.8%
versus 2016, when the company's sales were ¥52.70 billion.
Sales at Eps Corp have increased during each of the previous five years
(and since 2012, sales have increased a total of 72%).
Sales of Eps Business saw an increase
that was more than double the company's growth rate: sales were up
57.0% in 2017, from
¥3.94 billion to ¥6.18 billion.
Eps Corp also saw significant increases in sales in
Global Research Business (up 19.8% to ¥4.80 billion)
Not all segments of Eps Corp experienced an increase in sales in 2017:
sales of Others fell 80.3% to ¥294.00 million.
(However, this segment's sales were only a very small portion of the company's overall sales).